This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bukowski, R. M. Articles by Elson, P. Search for Related Content PubMed PubMed Citation Articles by Bukowski, R. M. Articles by Elson, P.

Prognostic Factors in Patients with Advanced Renal Cell Carcinoma

Development of an International Kidney Cancer Working Group

¹ Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, Ohio; and ² Centre Leon Berard, Lyon, France

The identification of prognostic factors in patients with metastatic renal cell carcinoma represents an area of increasing interest. Multiple publications identifying pertinent clinical and laboratory variables have appeared since 1986. The current study of 353 patients with advanced disease treated at The Cleveland Clinic from 1987 to 2002 was conducted to additionally assess and validate a model proposed recently by investigators from Memorial Sloan-Kettering Cancer Center. The data presented are similar to those reported previously, which demonstrated that patients with metastatic renal cell carcinoma can be categorized into good-, intermediate-, and poor-risk groups, using readily available clinical factors. Additionally, comparability of patients in this database to a group treated recently in France was assessed. These two groups appear similar in their distribution of various clinical factors and survival. Finally, a group of international investigators has been developed to provide a comprehensive database of >4,000 patients with metastatic renal cell carcinoma to provide and validate a single model that can be used to predict survival. This project is now under way.

This article has been cited by other articles:

				J. M.G. Larkin, E. L.S. Kipps, C. J. Powell, and C. Swanton Review: Systemic therapy for advanced renal cell carcinoma Therapeutic Advances in Medical Oncology, July 1, 2009; 1(1): 15 - 27. [Abstract] [PDF]

				G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, A. Kapoor, E. Staroslawska, J. Sosman, D. McDermott, I. Bodrogi, et al. Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma N. Engl. J. Med., May 31, 2007; 356(22): 2271 - 2281. [Abstract] [Full Text] [PDF]

				D. Strumberg, J. W. Clark, A. Awada, M. J. Moore, H. Richly, A. Hendlisz, H. W. Hirte, J. P. Eder, H.-J. Lenz, and B. Schwartz Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors Oncologist, April 1, 2007; 12(4): 426 - 437. [Abstract] [Full Text] [PDF]

				J. S. Lam, A. Breda, A. S. Belldegrun, and R. A. Figlin Evolving Principles of Surgical Management and Prognostic Factors for Outcome in Renal Cell Carcinoma J. Clin. Oncol., December 10, 2006; 24(35): 5565 - 5575. [Abstract] [Full Text] [PDF]

				M. Parton, M. Gore, and T. Eisen Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer J. Clin. Oncol., December 10, 2006; 24(35): 5584 - 5592. [Abstract] [Full Text] [PDF]

				F. Donskov and H. von der Maase Impact of Immune Parameters on Long-Term Survival in Metastatic Renal Cell Carcinoma J. Clin. Oncol., May 1, 2006; 24(13): 1997 - 2005. [Abstract] [Full Text] [PDF]